Jung Woo, MD
Retina Specialist · Vienna, VANPI 1437214525
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Genentech USA, Inc. at 30.7% of the total. Reporting peaked in 2023 at $298 and has fallen 61.4% since, to $115 in 2025. That places this record below the midpoint for retina specialist clinicians in VA, where the typical reported total is $1,967.
Across 22 payments — averaging $41.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$280
- AbbVie$148
- Apellis Pharmaceuticals, Inc.$140
- Novartis$131
- Alcon$115
- Alimera Sciences, Inc.$78
- plus $19 from 1 others
What the payments were for
- Food & beverage$89298%
- Gifts$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 5 | $280 |
| AbbVie(2 entities) | 7 | $148 |
| Apellis Pharmaceuticals, Inc. | 2 | $140 |
| Novartis | 2 | $131 |
| Alcon | 1 | $115 |
| Alimera Sciences, Inc. | 4 | $78 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$911 in reported general payments places this provider in the 25th percentile of 41 retina specialist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 50 | $2,904 |
| Bromfenac Sodium | 27 | $2,885 |
| Difluprednate | 19 | $1,998 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 29 | $1,457 |
| Ketorolac Tromethamine | 29 | $890 |
| MoxifloxacinMoxifloxacin Hcl | 41 | $816 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $531 |
| Latanoprost | 38 | $323 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Vienna
- Dal ChunVienna$12K
- Nishi GulatiVienna$602
- Jordana FeinManassas$412K
- Joaquin TosiVirginia Beach$48K
- Mohit NandaCharlottesville$31K
- Muge KesenMc Lean$30K
- Anna MackinRoanoke$26K
- Jon AdlebergChesapeake$21K
- Kori ElkinsPortsmouth$9K
- Jiwei ShengFairfax$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.